ZBIO: Rega marang dodolan Zenas Corp
Zenas Biopharma Inc (ZBIO) is rapidly strengthening its reputation among investors and physicians. A diversified pipeline for treating autoimmune pathologies minimizes risks, while the development of multi-specific antibodies provides access to multi-billion dollar markets. The ratio of valuation to sales volumes demonstrates demand dynamics, where 173.30 represents the latest level, helping to assess the risk of the asset being overbought relative to actual revenue.
Rincian analitis perusahaan Zenas Corp (ZBIO)
- rega saham lan target rega konsensus:
- informasi kapitalisasi pasar:
- data nilai buku modal saham:
- rincian struktur utang lan likuiditas bisnis:
Rasio Utang marang Ekuitas Zenas Biopharma Inc|ZBIO - Utang jangka dawa marang modal|Utang jangka cendhak marang modal zenasbio.com|ZBIO - Utang perusahaan|Utang-utang marang aset resik Zenas Biopharma Inc|ZBIO - Kewajiban jangka dawa perusahaan|Silihan lan utang jangka cendhak perusahaan Zenas Biopharma|Likuiditas cepet zenasbio.com
- indikator bathi lan kelipatan valuasi:
ZBIO - Bathi resik|Prakiraan bathi perusahaan Zenas Biopharma Inc|ZBIO - Rasio rega marang bathi|Rasio prakiraan rega marang bathi Zenas Corp|ZBIO - Rasio rega marang bathi tumrap wutah|Rasio nilai perusahaan marang bathi operasional sadurunge panyusutan Zenas Corp|ZBIO - Bathi operasional EBITDA|Bathi saben saham sajroning taun lumaku Zenas Biopharma|ZBIO - Bathi resik saben saham (EPS TTM)|Wutah bathi EPS kuartalan zenasbio.com|ZBIO - Wutah bathi saben saham ing taun lumaku|Dinamika bathi saben saham sing diarepake ing taun ngarep Zenas Biopharma Inc
- rincian pendapatan lan dodolan emiten:
Analisis fundamental perusahaan:ZBIO, Zenas Biopharma, Inc.
Zenas Biopharma Inc (ZBIO) develops immune biologics amidst complete geopolitical stability and diversified supply chains. The P/S trajectory reflects the market value of one dollar of annual revenue, allowing investors to assess the premium paid for current sales and avoid purchasing the asset at a valuation peak before a potential shift in the market cycle.
Karo sapa Zenas Biopharma Inc saingan
argenx - Rasio kapitalisasi marang pendapatan|Multiplikator P/S BNTX (biontech.de)|Abivax Corp (ABVX) - Rega marang dodolan|ADMA Corp - Multiplikator P/S|Rasio rega marang dodolan PTGX|Immunovant Inc (IMVT) - Rasio rega marang pendapatan|KNSA - Koefisien rega marang pendapatan|GRFS (Grifols Biemat) - Multiplikator P/S|Multiplikator P/S Adaptive Biotechnologies Inc.|Rasio rega marang pendapatan Celldex Therapeutics (CLDX)|Koefisien rega marang pendapatan auriniapharma.com|Rasio rega marang pendapatan BioCryst Pharmaceuticals BCRX|Rasio kapitalisasi pasar marang pendapatan VERA|Dianthus Pharma - Multiplikator P/S|PHVS - Multiplikator P/S|ABCL: Multiplikator P/S|TRML (Tourmaline Bio, Inc.) - Rasio rega marang pendapatan|Rasio rega marang pendapatan Intrexon|PHAR - Multiplikator rega marang pendapatan|Multiplikator P/S NKTR|Rasio rega marang pendapatan UPB (Upstream Bio Corp)|Multiplikator P/S IMNM (immunome.com)|Gossamer Bio, Inc. - Rasio rega marang pendapatan|KalVista Pharmaceuticals, Inc. - Multiplikator P/S|SEPN (Septerna) - Rasio kapitalisasi marang pendapatan|Pieris Corp (PVLA) - Rasio rega marang pendapatan|SVRA - Koefisien rega marang pendapatan|RIGL (rigel.com) - Multiplikator P/S|Rasio kapitalisasi marang pendapatan ANAB (AnaptysBio, Inc.)|Multiplikator P/S ATXS|enGene Holdings Inc (ENGN) - Multiplikator rega marang pendapatan|Multiplikator P/S RAPT (RAPT Therapeutics Inc.)|JBIO (Aerovate) - Rasio rega marang dodolan|ACRS: Kapitalisasi marang pendapatan|KYTX - Multiplikator P/S|TLSA: Multiplikator P/S|Kapitalisasi marang pendapatan Cabaletta Bio, Inc|Rasio rega marang pendapatan Ventyx Biosciences, Inc|THTX: Rasio kapitalisasi pasar marang pendapatan|Kapitalisasi marang pendapatan AVTX (Avalo Therapeutics, Inc)|Kapitalisasi marang pendapatan Eledon Pharmaceuticals ELDN|Rasio rega marang pendapatan Agenus, Inc. AGEN|Multiplikator P/S Climb Bio Inc. CLYM|ZURA - Rasio rega marang pendapatan|Rasio rega marang dodolan ATYR|ADAG (Adagene Inc.) - Kapitalisasi marang pendapatan|ImageneBio Inc (IMA) - Multiplikator P/S|Rasio rega marang pendapatan Shattuck Therapeutics|Kapitalisasi marang pendapatan equilliumbio.com (EQ)|Multiplikator P/S CNTB|Koefisien rega marang pendapatan Immunic Therapeutics|Multiplikator P/S ATRA (Atara Biotherapeutics, Inc.)|IFRX - Kapitalisasi marang pendapatan|Rasio kapitalisasi pasar marang pendapatan X4 Pharmaceuticals, Inc. (XFOR)|ACET (adicetbio.com) - Rasio kapitalisasi marang pendapatan|CELU: Multiplikator P/S|INMB - Koefisien rega marang pendapatan|Rasio rega marang pendapatan Barinthus Biotherapeutics plc|KZR: Rasio kapitalisasi pasar marang pendapatan|Multiplikator P/S SABS|AKTX (Akari Therapeutics Plc) - Rasio kapitalisasi pasar marang pendapatan|Multiplikator P/S ENLV (Enlivex Therapeutics Ltd)|q32bio.com - Rasio rega marang pendapatan|GOVX: Kapitalisasi marang pendapatan|edesabiotech.com (EDSA) - Kapitalisasi marang pendapatan|IBIO: Multiplikator P/S|CARM - Koefisien rega marang pendapatan|Kapitalisasi marang pendapatan XTLB|Kapitalisasi marang pendapatan boltbio.com (BOLT)|Rasio rega marang pendapatan HCW Biologics Inc (HCWB)|Multiplikator P/S Aptevo Therapeutics, Inc. (APVO)|Rasio rega marang pendapatan aimimmuno.com AIM|Rasio kapitalisasi pasar marang pendapatan ADTX|GRI Bio Corporation - Multiplikator P/S|XORTX Corp (XRTX) - Kapitalisasi marang pendapatan|HIND (Vyome Holdings Inc.) - Kapitalisasi marang pendapatan|revbiosciences.com (REVB) - Multiplikator P/S|INDP (Indaptus Corp) - Multiplikator P/S|Kapitalisasi marang pendapatan Scinai Immunotherapeutics Ltd (SCNI)|Rasio rega marang pendapatan CalciMedica Inc (CALI)|AFMD (Affimed NV) - Rasio kapitalisasi pasar marang pendapatan|Multiplikator P/S ALLK (Allakos Inc.)|Multiplikator P/S HOOKIPA HOOK|IGMS: Kapitalisasi marang pendapatan|Rasio kapitalisasi pasar marang pendapatan ITOS (iTeos)|OCEA: Multiplikator P/S|TCBP (TC BioPharm Ltd) - Rasio rega marang pendapatan|THRD (Third Harmonic Bio Inc) - Multiplikator P/S
